沈穎　周劍

【摘要】 目的：探討表柔比星聯合多西他賽治療乳腺癌的應用效果。方法：選擇2013年6月-2014年11月乳腺癌患者90例，根據治療方法分兩組。兩組均應用多西他賽聯合表柔比星新輔助化療，對照組先采用表柔比星，之后應用多西他賽，觀察組則先用多西他賽，之后應用表柔比星。比較兩組乳腺癌治療效果，生存時間，治療前后患者卡氏評估分值、體力狀況、FACT-B生存質量評分。結果：觀察組乳腺癌治療效果優(yōu)于對照組，差異有統(tǒng)計學意義（P<0.05）；觀察組生存時間長于對照組，差異有統(tǒng)計學意義（P<0.05）；治療前兩組卡氏評估分值、體力狀況、FACT-B生存質量評分相近（P>0.05）；治療后觀察組卡氏評估分值、體力狀況、FACT-B生存質量評分均優(yōu)于對照組，差異均有統(tǒng)計學意義（P<0.05）。結論：乳腺癌治療中應用多西他賽聯合表柔比星新輔助化療的效果確切，但藥物應用順序可影響治療效果，推薦先應用多西他賽再用表柔比星，以更好改善病情和生活質量。

【關鍵詞】 表柔比星； 多西他賽； 乳腺癌； 應用效果

doi：10.14033/j.cnki.cfmr.2018.22.003 文獻標識碼 A 文章編號 1674-6805（2018）22-000-03

Effect Analysis and Evaluation of Docetaxel Combined with Epirubicin Neoadjuvant Chemotherapy in the Treatment of Breast Cancer/SHEN Ying，ZHOU Jian.//Chinese and Foreign Medical Research，2018，16（22）：-8

【Abstract】 Objective：To investigate the effect of Epirubicin combined with Docetaxel in the treatment of breast cancer.Method：90 cases of breast cancer from June 2013 to November 2014 were divided into two groups according to the treatment method.The two groups were treated with Docetaxel plus Epirubicin neoadjuvant chemotherapy.The control group was treated with Docetaxel after the first use of Epirubicin.The observation group was treated with Docetaxel then followed Epirubicin.The treatment effect of two groups of breast cancer was compared，the time of survival，the score of Karnofsky evaluation before and after treatment，the physical condition and the quality of life of FACT-B were compared before and after the treatment.Result：The observation group of breast cancer treatment was higher than the control group（P<0.05）；the observation group of survival time was longer than the control group（P<0.05）.The two groups before treatment，the Karnofsky evaluation score，physical status，FACT-B quality of life score were similar（P>0.05）；after treatment，the observation groups Karnofsky evaluation score， physical status，FACT-B quality of life score were better than those of the control group（P<0.05）.Conclusion：Docetaxel combined with Epirubicin neoadjuvant chemotherapy is effective in the treatment of breast cancer，but the sequence of drug application can affect the therapeutic effect.It is recommended that Docetaxel should be applied first，and then Epirubicin，so as to improve the condition and quality of life.

【Key words】 Epirubicin； Docetaxel； Breast cancer； Application effect

First-authors address：Xianning Central Hospital，Xianning 437100，China

乳腺癌患者近年來越來越多，是女性常見的惡性腫瘤之一[1]。乳腺癌首選手術治療，而輔術前新輔助化療和術后化療也非常重要，有利于進一步殺滅殘留腫瘤細胞，降低復發(fā)率。但目前關于新輔助化療方案的選擇仍存在爭議。多西他賽是一種紫杉類抗腫瘤藥物，其抗癌作用在于抑制微管解聚，強化微管蛋白聚合作用。而表柔比星為蒽環(huán)類抗癌藥物，可影響DNA和RNA合成[1-2]。為了探討乳腺癌患者的有效新輔助化療方法，本研究選擇2013年6月-2014年11月乳腺癌患者90例，根據治療方法分兩組，分析了表柔比星聯合多西他賽治療乳腺癌的應用效果，報告如下。